TNFSF10, TNF superfamily member 10, 8743

N. diseases: 445; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Hence, this review summarizes recent progress in studies on TRAIL, including its role in apoptotic signaling, potential therapeutic applications of TRAIL in HCC, hepatitis virus infection, and liver fibrosis and cirrhosis. 30544063 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Thymoquinone upregulates TRAIL/TRAILR2 expression and attenuates hepatocellular carcinoma in vivo model. 31336121 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE In addition, we revealed that CASC2, a well-established tumor suppressive long non-coding RNA, could serve as a "Sponge" of miR-24 and miR-221, thus modulating TRAIL-induced tumor cell apoptosis TRAIL resistance of hepatocellular carcinoma. 29476051 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE This study aimed to evaluate chloroquine's (CQ) ability to trigger TRAIL/TRAILR2 apoptotic pathway in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) either alone or in combination with doxorubicin (DOX). 29133031 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Evidence has shown that most hepatocellular carcinoma (HCC) cells are resistant to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. 29444104 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice. 28885731 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Synergistic Anti-tumour Effects of Quercetin and Oncolytic Adenovirus expressing TRAIL in Human Hepatocellular Carcinoma. 29391509 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE Herein we investigated the antitumor activity and safety of mono- and combined therapy with OAds armed with ING4 (Ad-ΔB/ING4) and TRAIL (Ad-ΔB/TRAIL) gene, respectively, on preclinical models of human HCC. 28925992 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE However, whether such change of miRNA on TRAIL sensitivity is seen in hepatocellular carcinoma still needs to be explored. 28410209 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Therefore, authors introduced new integration between gene therapy and nanotechnology in the form of PTEN and TRAIL-loaded ZNPs that proved potential to be used in gene therapy for the treatment of HCC. 28140697 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE Herein, we investigated the therapeutic efficacy of concurrent therapy with two armed oncolytic adenoviruses encoding human TRAIL gene (Ad-ΔB/TRAIL) and IL-12 gene (Ad-ΔB/IL-12), respectively, on preclinical models of human HCC, and also elucidated the possible underlying mechanisms. 27154307 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Since the cancer stem cells (CSCs) are believed to be responsible for the treatment failure in multiple cancers including hepatocellular carcinoma (HCC), the aim of this study was to investigate the strategies to increase the sensitivity of liver cancer stem cells (LCSCs) to TRAIL. 27840896 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Correlation analysis revealed significantly lower TRAIL expression in HCC samples with the -1573C sequence (P ≤ 0.05). 27580702 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Forced expression of Msi1 decreased the sensitivity of HCC cells to TRAIL both in vitro and in vivo. 25747387 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Evidence has shown HCC cell resistance to TRAIL‑mediated apoptosis. 25607597 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE The results of this study suggest that low TRAIL mRNA levels may be both a dominant feature in HCC development and growth and a predictor of tumor recurrence and poorer survival rates. 25123818 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE In addition, experiments in both hepatocellular carcinoma and melanoma-bearing mice demonstrated that the genetically engineered rNDV-IL-2-TRAIL exhibited prolonged animals' survival compared with rNDV, rNDV-IL-2, and rNDV-TRAIL. 24971746 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Collectively, the results of the present study indicate that BM-MSC can provide a steady source of stTRAIL and may be suitable for use in the prevention of the recurrence of hepatocellular carcinoma after RFA with secretable trimeric TRAIL. 24451114 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Although TRAIL and its receptors are selective targets for cancer therapy, their potential against HCC with chronic HCV infection has not been explored yet. 24927176 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE The purpose of this study was to explore whether Gli2 silencing enhances efficiency of TRAIL for hepatoma in vivo. 25535898 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Insights from TRAIL mediated signaling in HCC research are catalyzing new lines of study that should not only explain molecular mechanisms of disease but also highlight emerging paradigms in restoration of TRAIL mediated apoptosis in resistant cancer cells. 25037270 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE ABT-263, a second-generation BH3 mimic, binds to the anti-apoptotic family members Bcl-2, Bcl-xL and Bcl-w, and has been demonstrated to enhance TNFSF10 (TRAIL)-induced apoptosis in human hepatocarcinoma cells. 24571452 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Fn14•TRAIL induced robust apoptosis of multiple HCC cell lines, while sparing non-malignant hepatocyte cell lines. 24130833 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE The novel CTL harboring Lenti/hCD40L/E1AB and Ad5/35-TRAIL caused proliferation inhibition and significant apoptosis in hepatocellular carcinoma cell lines. 23825554 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE These results in human hepatocarcinoma cell lines and primary hepatocytes provide a rationale for testing the combination of salirasib and TRAIL agonists in human hepatocarcinoma. 23348585 2013